Proteins are the "workers" in the biochemistry of life and are critical to almost everything your body does, but sometimes, they can also cause or contribute to disease. RNAi therapeutics, which were pioneered by Alnylam, work by preventing the production of specific unwanted proteins. #ScienceCurious to learn more about the science of #RNAi? Read more here: https://bit.ly/3oR8r2l #RNAiTherapeutics #siRNA #GeneSilencing #science
Alnylam Pharmaceuticals
Biotechnology Research
Cambridge, Massachusetts 196,451 followers
Alnylam is the leading RNAi therapeutics company. We're a fast-growing biopharma with a deep pipeline and global reach.
About us
To those who say “impossible, impractical, unrealistic,” we say: “CHALLENGE ACCEPTED.” Alnylam is the world's leading RNAi therapeutics company and the first and only company to bring RNAi-based medicines to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today’s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Alnylam is turning scientific possibility into reality - in 2018, the FDA and EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. We now have four additional medicines on the market. Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of 2,000 people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we've been named a Science Magazine Top Employer 5 years in a row ('19-'23), a Boston Globe Top Place to Work 9x in a row ('15-'23) and Fast Company's #1 Best Workplace for Innovators ('22). We are based in Cambridge, U.S., with offices throughout Europe, Asia, and South America. See our community guidelines: https://bit.ly/2FcRhJy.
- Website
-
http://www.alnylam.com
External link for Alnylam Pharmaceuticals
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Public Company
- Founded
- 2002
- Specialties
- Biotech, Pharmaceuticals, Biopharma, Drug Development, Rare Diseases, and RNAi
Locations
Employees at Alnylam Pharmaceuticals
Updates
-
What a week last week! Every Alnylam achievement, RNAi therapeutics advancement and milestone (such as our HELIOS-B topline data, which we were celebrating), is made possible because of the passion, innovation and perseverance of our 2,000 employees who are unwavering in their dedication to our mission. Together, we are leading the #RNAiRevolution. #RNAiTherapeutics #RNAi #siRNA #CompanyCulture
-
-
-
-
-
11
-
-
Healthcare Professionals: #hATTR #amyloidosis is a progressive and often fatal disease that affects multiple organs and tissues, resulting in a highly varied symptom presentation. Learn more about some different patient types that could be in your practice. https://bit.ly/3NuMgL9
-
RNA interference (RNAi) is a naturally occurring process of gene regulation that is already at work inside your body. RNAi therapeutics, which were pioneered by Alnylam, utilize this process to silence the genes that cause or contribute to disease. #ScienceCurious to learn more about #RNAi? Click here: https://bit.ly/3oR8r2l #RNAiTherapeutics #siRNA #GeneSilencing #RNA
-
An Alnylam team took steps to raise funds for the Huntington's Disease Society of America —literally. 👣 With kids in tow, colleagues participated in Team Hope Walk last weekend on Castle Island in Boston. We’re raising awareness about this devastating #RareDisease. Learn more about #HuntingtonsDisease: https://hdsa.org/
-
-
Alnylam Pharmaceuticals reposted this
It gives me immense PRIDE to attend events like today’s ‘Show your PRIDE’ lunch at Alnylam in Zug. At @AlnylamPharmaceuticals, our PRIDE theme is Diverse Equal Proud. It’s about recognizing the diversity of people within the LGBTQ community and the fact that everyone deserves to be proud of who they are and treated with equal respect and dignity, regardless of gender, ethnicity or background. As an Executive Sponsor of our employee network SAGA – the Sexuality And Gender Alliance – it’s wonderful to see the company come together to celebrate PRIDE Month, showing our support and allyship. Throughout June, Alnylam has been proudly decorated with rainbows – from rainbow Zoom backgrounds to rainbow lanyards, and a variety of colorful PRIDE-themed events have been held across our offices globally to celebrate acceptance and diversity. I’m very proud to be an ally and to work at a company that lives and breathes its commitment to inclusivity as strongly as Alnylam does. It is so important that everyone feels able to bring their authentic self to work, and to be accepted and respected for who they truly are. I have such huge admiration for everyone who has trailblazed the path to improving LGBTQ acceptance across the world, and to all those I know – at Alnylam and beyond – who have been on their own personal LGBTQ journeys. But I also know so much progress is still to be made, and each and every one of us needs to play a part in supporting this. #PRIDEmonth #PRIDE2024 #alnylamproud
-
-
Dr. Fontana, an investigator on the HELIOS-B Phase 3 study of vutrisiran, an investigational #RNAi therapeutic in development for the treatment of #ATTR #amyloidosis with cardiomyopathy, shares her thoughts on the positive topline results. Full results will be presented at an upcoming medical meeting. #RNAiTherapeutics
-
-
Our CEO Dr. Yvonne Greenstreet shares her thoughts on the positive Phase 3 topline results from our HELIOS-B study of vutrisiran, an investigational #RNAi therapeutic in development for the treatment of #ATTR #amyloidosis w/ cardiomyopathy. Read the press release: https://bit.ly/3VwvRtY #RNAitherapeutics #siRNA
-
This morning, during a live webcast, we’ll discuss topline results from our HELIOS-B Phase 3 study of vutrisiran, an investigational #RNAi therapeutic in development for the treatment of #ATTR #amyloidosis with cardiomyopathy. Access the webcast: https://bit.ly/374c75E #RNAiTherapeutics #siRNA
-
-
We are pleased to share positive topline results from our HELIOS-B Phase 3 study of vutrisiran, an investigational #RNAi therapeutic in development for the treatment of #ATTR #amyloidosis with cardiomyopathy. Read the press release: https://bit.ly/3VwvRtY #RNAiTherapeutics #siRNA
-
Similar pages
Browse jobs
Stock
ALNY
NASDAQ
20 minutes delay
$251.03
2.35 (0.945%)
- Open
- 246.95
- Low
- 246.95
- High
- 252.48
Data from Refinitiv
See more info on